Feb. 26 (UPI) -- The Food and Drug Administration's vaccine committee will meet Friday morning to consider recommendation for the Johnson & Johnson coronavirus vaccine, one of the final steps in approving it for use in the United States.
The FDA's Vaccines and Related Biological Products Advisory Committee will convene at 9 a.m. EST to consider the vaccine, which is manufactured by Johnson & Johnson subsidiary Janssen.
The committee will ultimately decide whether to recommend the vaccine for emergency use in the United States, which then must meet similar approval by FDA leadership. Once that occurs, as well as approval by the Centers for Disease Control and Prevention, the vaccine would be the third approved and distributed nationally.
Once the FDA's vaccine committee makes its recommendation, however, it is usually quickly followed by final approval by the agency and the CDC's Advisory Committee on Immunization Practices.
The available vaccines from Pfizer and Moderna went through this process in mid-December.
Johnson & Johnson's vaccine is different from the other two, in that it is adenovirus-based as opposed to messenger RNA, like those from Pfizer and Moderna. Also, it is a one-shot vaccine, without a need for a booster and can be stored and transported at much warmer temperatures than the other two formulations.
An FDA analysis on Wednesday confirmed the vaccine's effectiveness, which was shown in clinical trials to be about 66% effective for all human volunteers in the United States, Latin America and South Africa. It was shown to be 85% effective in preventing severe COVID-19.